Factor XI Inhibitor

Abelacimab in Atrial Fibrillation: Impact of Prior Anticoagulation Experience on Bleeding Risk

The AZALEA-TIMI 71 study demonstrates that factor XI inhibition with abelacimab reduces bleeding risk in atrial fibrillation patients regardless of prior oral anticoagulation experience, with a potentially greater absolute benefit in antico